Latest Conference Articles

Emapalumab May Improve Response Rates in MAS Treatment

Electronic messages highlighting cardiovascular benefits of flu shots increased vaccination rates by 1.8% in heart attack survivors.

Alexei Grom, MD, Research Director, Division of Rheumatology, and Professor, Department of Pediatrics, Cincinnati Children’s

Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage in HFpEF

Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.

Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage | Image Credit: Mayo Clinicn HFpEF

By Barry A. Borlaug, MD
Connor Iapoce

Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis

Barry A. Borlaug, MD describes the beneficial effect of tirzepatide on circulatory pressure-volume overload and end-organ damage in patients with HFpEF and obesity.

ITCH-E: Pruritus Linked to Worse Health-Related Quality of Life in PBC

Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.

Minjee Kim, MD: Understanding Sleep’s Impact on Post-Liver Transplant Outcomes

Patients with PBC and moderate/severe pruritus face a greater health-related quality of life burden and impaired activity than those with no/mild itch.

GLORIOUS: Exenatide Lacks Preventive Effect on Organ Injury in Cardiac Surgery

Kim explains how poor sleep is linked to negative impacts on mental health, physical health, and frailty after liver transplantation.

Oussama Wazni, MD, MBA: OPTION Trial and the Role of LAAC in Atrial Fibrillation

An IV infusion of exenatide during cardiac surgeries involving bypass did not significantly benefit mortality or organ injury compared with placebo.

By Oussama Wazni, MD
Patrick Campbell

Oussama Wazni, MD, discusses the results of the OPTION trial examining LAAC in atrial fibrillation as well as its reception as AHA 2024.

Aleenah Mohsin, MD, MBBS | Credit: American Heart Association

By Patrick Campbell

Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD

Obesity-related ischemic heart disease deaths rose from 1999 to 2020, particularly in middle-aged men and Black adults, per CDC WONDER data.

Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD

Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.

TCE Therapy Demonstrates Quick Responses for Systemic Lupus Erthematosus in Early Data

Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.

Qiubai Li, MD, PhD, director, rheumatology, Union Hospital, and Huazhong University of Science and Technology

Elafibranor Improves Predicted Transplant-Free Survival Based on GLOBE, UK-PBC Scores

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

Kris Kowdley, MD | Credit: Velocity Clinical Research

Interim Phase 1 Update Shows Favorable Effect of Nex-z for ATTR-CM

Treatment with elafibranor (Iqirvo) improved prognostic GLOBE and UK-PBC scores as early as week 4 in the phase 3 ELATIVE trial.

VANISH2: Catheter Ablation Viable First-Line Option for Ventricular Tachycardia

A single dose of nex-z achieved consistent and rapid reductions in serum TTR levels over 12 months of follow-up in patients with ATTR-CM.

Chari Cohen, DrPH, MPH: Healthcare Providers’ Role in HBV Clinical Trial Diversity

Initial catheter ablation achieved a lower risk of a composite primary endpoint event than anti-arrhythmic drug therapy in patients who survived a heart attack.

Chari Cohen, DrPH, MPH | Credit: LinkedIn

Rapid Initiation of SGLT2 Inhibitors Improves Cost-Effectiveness of Therapy, with Ankeet Bhatt, MD, MBA

Cohen explains patient perspectives about how healthcare providers can help address the lack of diversity in chronic HBV clinical trials.

By Ankeet Bhatt, MD, MBA
Patrick Campbell

Hide Okuno, MS: Tube Weaning Reduces Parental Stress, Findings Guide Future Studies

Ankeet Bhatt, MD, MBA, discusses a study he led from AHA 2024 examining the cost-effectiveness of dapagliflozin based on how soon therapy was initiated following diagnosis or hospitalization.

By Chelsie Derman

Vitamin D Deficiency Linked to Worse Autoimmune Hepatitis Outcomes

At NASPGHAN 2024, Okuno shared findings on reduced parental stress after children’s tube weaning, emphasizing the potential for new outpatient weaning protocols.

Mariana Nunes Ferreira, MD | Credit: Mariana Nunes Ferreira on X

Jonathan Stine, MD: Exercise’s Benefit in MASH is Independent of Weight Loss

Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.

Jonathan Stine, MD | Credit: Penn State Health

Intensive Blood Pressure Regimen Lowers CVD Risk in People with T2D

Stine reviews findings from a posthoc analysis of the NASHFit trial suggesting the impact of exercise on MASH resolution, even without weight loss.

SUMMIT Trial Proves Tirzepatide's Benefit in HFpEF with Obesity

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

Milton Packer, MD | Credit: American Heart Association

By Patrick Campbell

Telehealth Could Address HCV Care Barriers, Expand Treatment for People Who Inject Drugs

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.

Zoi Papalamprakopoulou, MD | Credit: Papalamprakopoulou on LinkedIn

John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study

Zoi Papalamprakopoulou, MD, explains telehealth’s potential to aid HCV treatment in high-risk populations and how patients perceive this care modality.

Glucocorticosteroid Use for Rheumatoid Arthritis Increases CVD, Infection Mortality Risk Even After Cessation

Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.

Diane Lacaille, MDCM, MHSc, Scientific Director and Senior Scientist at Arthritis Research Canada and Professor, Department of Medicine, University of British Columbia, Vancouver.

Study Highlights Real-World Characteristics of Providers Treating Psoriasis in US

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

Study Highlights Real-World Characteristics of Providers Treating Psoriasis in the US

By Tim Smith

Wei Zhang, MD, PhD: Optimizing Post-Liver Transplant Care for High-Risk Patients

In this cross-sectional survey analysis, new insights were explored regarding clinical practice patterns and treatment outcomes within dermatology practices in the US.

Idorsia Launches Aprocitentan (TRYVIO) in US For Treatment of Hypertension

Zhang describes how a novel multidisciplinary care clinic has helped reduce relapse after transplant in patients with alcohol-associated liver disease.